---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-24-000029"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:50:11.186184+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Mirum Q2 net product sales $77.8M (+139% YoY); LIVMARLI sales $47.2M; positive volixibat interim data

## Summary
- Q2 2024 global net product sales $77.8M, up 139% vs Q2 2023; full-year guidance reaffirmed at $310-320M.
- LIVMARLI net sales $47.2M (+45% YoY); combined CHOLBAM/CHENODAL sales $30.5M.
- Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies.
- LIVMARLI approved in Europe for PFIC (≥3 months) and US label expanded to ≥12 months; NDA filed for chenodiol in CTX.
- Cash & investments $295.4M (Dec 2023: $286.3M); operating expenses $102.1M vs $61.8M YoY.

## SEC filing metadata
- accession: 0001759425-24-000029
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000029/0001759425-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000029/mirm-20240807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-24-000029
- JSON: https://secwatch.observer/filing/0001759425-24-000029.json
- Plain text: https://secwatch.observer/filing/0001759425-24-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.